Ziltivekimab is under clinical development by Novo Nordisk and currently in Phase III for Diastolic Heart Failure (HFpEF). According to GlobalData, Phase III drugs for Diastolic Heart Failure (HFpEF) ...

managed parking lots, you open up a real avenue to housing. He said he remembers the “battles” over homelessness before Safe Parking gave them a “better way,” with numbers to back it up: The program ...

Shares of drugmaker Novo Nordisk (NVO) sold off sharply last week, falling as much as 29% intraday Friday (before closing down 17%) and wiping out nearly $100B of market value in the process when ...

(CNN) — Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more ...

COPENHAGEN, Dec 20 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of 2025 that it ...

Novo Nordisk falls most on record after new weight drug disappoints Novo’s shares plunged as much as 27 per cent, and they’re now down 17 per cent for the year after a previous runup on the strength ...

WASHINGTON (AP) — Specialty pharmacies and online companies that have been selling off-brand copies of two blockbuster drugs for obesity and diabetes will need to phase out their versions next ...

With those slides, both were tracking to see their worst weekly performances of 2024. Shares of Novo Nordisk plunged more than 16% in afternoon trading, putting the stock on track for its worst ...

Within the Medicare prescription drug benefit, the amount spent on diabetes medicines like the popular newer GLP-1 medicines such as Novo Nordisk's Ozempic and Wegovy that are also used for weight ...

This story was updated to add new information. The parent company of Danish drug maker Novo Nordisk said it completed its $16.5 billion purchase of Catalent, including the Bloomington operations ...

Novo Nordisk, for its part, has been working hard to enrich its cardiometabolic pipeline in areas beyond diabetes and obesity, where the company currently dominates the commercial market with its ...